Rapid Advancement Across Core R&D Pipeline

• The global, multicenter Phase I/II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) is actively enrolling patients in Australia and China, and the Phase II IND application has been approved in the US. CS2009 demonstrates an excellent safety profile with a ≥Grade 3 TRAE rate of 23%,...